top of page

Ongoing Clinical Trials in
Focal segmental glomerulosclerosis (FSGS)

Inaxaplin


People with homozygosity or compound heterozygosity for G1 and G2 risk alleles are at high risk of developing multiple kidney diseases...

Sparsentan


Sparsentan is a novel single-molecule dual endothelin (ET-1) and angiotensin receptor antagonist with hemodynamic...

DMX-200 (Repagermanium)


Repagermanium is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an angiotensin II receptor...

Baricitinib: JUSTICE trial


Baricitinib inhibits Janus kinase (JAK) enzymes, which are intracellular enzymes involved in stimulating hematopoiesis and immune cell...

Metformin


Metfromin (MF) which is the most commonly used antidiabetic medications has been found to activate the AMP-activated protein...

Multiple Targets for Novel Therapy in FSGS

FSGS.Novel ttargets pdf.jpg

List of Updated Clinical Trials for Focal segmental glomerulosclerosis (FSGS)

bottom of page